asa glp 1 agonist guidelines The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on New therapeutic agents for type

Under the Human Medicines Regulations 2012, the supply and advertising of unlicensed medicines for human use is restricted

Despite this, some clinics administer BPC-157 obtained from research peptide suppliers, offshore pharmacies, or gray-market manufacturers

If you want to layer satiety pathways, cagrilintide is a compelling stack candidate with GLP-1s

To address that gap, CMS launched a temporary Medicare GLP-1 Bridge program: starting July 1, 2026, eligible beneficiaries can access certain GLP-1 medications for about $50 per month, with eligibility tied to BMI thresholds (for example, a BMI of 35 or higher, or 27 or higher with other clinical criteria)